Cover Image

China: Anti-Diabetic Drug Market Report 2008

Notice
This publication has been discontinued on May 18, 2013.

Abstract

Diabetes Mellitus (DM) is a chronic disease that occurs when the pancreas does not produce enough insulin, or alternatively, when the body cannot effectively use the insulin it produces.

When China started its economic reform in 1978, the diabetes disease rate was about 0.6% in the Chinese population. As China entered the rapid growth phase of its economic development, the diabetes disease rate has arisen rapidly. In 1995, the diabetes disease rate reached 1.5% and in 2000 the diabetic disease rate was 2.4% with the total number of diabetes patients at 31 million in China. The average addition of new diabetes patients each year was about 1.5 millions. Due to the increased numbers of diabetes patients and the improvements of living standards, the market size of diabetes drugs has increased steadily in China. The market size of diabetes drugs in 2002 was about RMB 4.187 billion and increased to RMB 7.495 billion in 2007 (USD 1.071 billion at 7:1 USD:RMB exchange rate) with an average annual growth of 13%. The annual growth rate from 2006 to 2007 was a significant 20.98%.

This report has systemically analyzed the Chinese diabetes drug market. All drug data are based on hospital drug prescription and drug purchasing data from the hospital data monitor system that the China Nan Fang Institute of Medical and Economic Information has developed and maintained (Nan Fang Institute is a direct subsidiary of the Chinese State Food and Drug Administration, the SFDA). Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou, covering significant percentages of all hospitals in these regions.

Market shares from all major players including multinational and Chinese pharmaceutical companies and their major diabetes products are analyzed systemically based on data from significant number of Chinese hospitals. The comprehensive hospital utilization data of major diabetes drugs will present you a clear picture of the competition landscape of Chinese diabetes drug market and the market potential for your company' s product(s) that already marketed in China or if you are planning to bring your drugs to the China market.

This China Diabetes Drug Market Report has been a Must-have reference for all levels of decision makers in pharmaceutical companies, medical device companies, healthcare investing companies and healthcare consulting companies. These unique drug prescription and utilization data can provide valuable information for new product development, marketing and strategic planning functions for pharmaceutical companies. Compared to expensive customized drug reports in China, this multi-client report provides significant savings and great cost/benefit to pharmaceutical companies and interested parties.

Table of Contents

METHODOLOGY FOR THE ANNUAL CHINA DRUG MARKET REPORTS

CHAPTER I - SUMMARY OF THE ANTI-DIABETIC DRUG MARKET

  • Section I: Overview of Diabetes in China
    • 1.1 Diabetes and Its Classification
    • 1.2 Diabetes Symptoms and Characteristics
    • 1.3 Complications of Diabetes
    • 1.4 Diabetes in China
  • Section 2: Summary of Anti-diabetic Drugs and their Classifications
    • 2.1 Key Oral Anti-diabetic Drugs (Western Medicine)
    • 2.2 TCM Blood-sugar Lowering Drugs
    • 2.3 Insulin and Related Drugs

CHAPTER II - SUMMARY OF THE GLOBAL ANTI-DIABETIC DRUG MARKET

  • Section 1: New Approvals of Anti-diabetic Drugs in 2007
  • Section 2: Summary of Global Anti-diabetic Drug Market
    • 2.1 Global Market Sizes and Growth Rates of Anti-diabetic Drugs (2004-2007)
    • 2.2 Anti-diabetic Drugs as the Top 5th Best Selling Category in 2007
    • 2.3 Anti-diabetic Drugs Listed among the Top 50 Best Selling Drugs in 2006
    • 2.4 Global Market Shares of Oral Anti-diabetic Drugs vs. Insulin and Insulin Analogs (2003-2007)

CHAPTER III - ANALYSIS OF THE CHINESE ANTI-DIABETIC DRUG MARKET

  • Section 1: Sizes and Annual Growth Rates of the Chinese Anti-diabetic Drug Market (2002-2007)
    • 1.1 Market Shares of Anti-diabetic Drugs by Category in China 2007
    • 1.2 Market Sizes of Key Anti-diabetic Drugs by Category in China 2007
    • 1.3 Sales and Manufacturers of the Top 10 Best Selling Oral Anti-diabetic Drugs in China 2007
    • 1.4 Growth Forecast of China' s Anti-diabetic Drug Market by 2012
  • Section 2: Hospital Market Shares of Anti-diabetic Drug Manufacturers
    • 2.1 Market Shares of the Top 20 Pharmaceutical Companies in the Chinese Anti-diabetic Drug Market (2005-2007)
    • 2.2 Sales of the Top 20 Pharmaceutical Companies in the Chinese Anti-diabetic Drug Market (2005-2007)
    • 2.3 Analysis of Market Concentration of the Top 4 and Top 8 Pharmaceutical Companies by Herfindahl-Hirschman Index
  • Section 3: Analysis of Hospital Market Shares and Annual Growth Rates of the Top 10 Best Selling Anti-diabetic Drugs in China (2005-2007)

CHAPTER IV MARKET SHARE ANALYSIS OF THE TOP 10 KEY ANTI-DIABETIC DRUGS & COMPETITORS IN CHINA

  • Section 1: Manufacturers, Market Sizes and Shares for Insulin
  • Section 2: Manufacturers, Market Sizes and Shares for Acarbose
  • Section 3:Manufacturers, Market Sizes and Shares for Metformin
  • Section 4:Manufacturers, Market Sizes and Shares for Repaglinide
  • Section 5:Manufacturers, Market Sizes and Shares for Rosiglitazone
  • Section 6:Manufacturers, Market Sizes and Shares for Glipizide
  • Section 7: Manufacturers, Market Sizes and Shares for Gliquidone
  • Section 8:Manufacturers, Market Sizes and Shares for Gliclazide
  • Section 9:Manufacturers, Market Sizes and Shares for Nateglinide
  • Section 10:Manufacturers, Market Sizes and Shares for Xiaoke Wan (Formulated)

CHAPTER V - LIST OF BRAND NAMES, GENERIC NAMES, PRICES AND MANUFACTURERS OF ANTI-DIABETIC DRUGS IN CHINA ANTI-DIABETIC DRUGS ON THE NATIONAL HEALTHCARE INSURANCE COVERAGE LIST

  • Section 1: Package, Unit, Retail Price of anti-diabetic Drugs and their Manufacturers in China
  • Section 2: Anti-diabetic Drugs on the National Healthcare Insurance and Work Injury Insurance List
    • 2.1 Types of Insurance, Formula and Reimbursement Restriction

CHAPTER VI R& D OF ANTI-DIABETIC DRUGS

  • Section 1: Non-insulin Treatments for Type II Diabetes
    • 1.1 Oral Anti-diabetic Drug as First Line Treatment
    • 1.2 New Treatment Options: Incretin Treatment
    • 1.3 Other Anti-diabetic Drugs under Phase II/III Clinical Studies
    • 1.4 The US Market of Anti-diabetic Drugs
  • Section 2: Anti-diabetic Drugs Recently Approved or Currently under Clinical Study
    • 2.1 Denmark' s Novo Nordisk Filed Regulatory Approval of its Type 2 Diabetes Drug Liraglutide in the US and Europe Simultaneously
    • 2.2 New Anti-diabetic Drug Development by Eli Lilly and Transition
    • 2.3 FDA Approved Novo Nordisk' s NovoLog for Treating Pediatric Diabetes Patients
    • 2.4 FDA Accepted UCB' s NDA Application for Lacosamide for the Treatment of Adults with Diabetic Neuropathic Pain
    • 2.5 US FDA Approved Amylin' s SymlinPen 120 and SymlinPen 60 Pen-injector Devices

CHAPTER VII - GOVERNMENT POLICIES FOR THE CHINESE ANTI-DIABETIC DRUG MARKET

EXHIBITS

Table A Hospital Coverage for the Monitoring and Tracking of Drug Prescription and Purchasing Data in China.

TABLES

  • Table 1: Complication in Chinese Diabetes Patients
  • Table 2: DM and IGT Disease Rates (%) in Different BMI Populations
  • Table 3: Newly Approved Anti-diabetic Drug (New Molecule Entity) in 2007
  • Table 4: The Top 10 Best Selling Drug Categories in the World in 2007
  • Table 5: Anti-diabetic Drugs on the List of the World Top 50 Best Selling Drugs in 2006
  • Table 6: Sales of Anti-diabetic drugs by Categories in China 2007
  • Table 7: Top 10 Best Sellers of Oral Anti-diabetic Drugs in China 2007
  • Table 8: Market Shares of the Top 20 Pharmaceutical Companies in the Chinese Anti-diabetic Drug Hospital Market 2005-2007
  • Table 9: Sales of Anti-diabetic drugs of the Top 20 Pharmaceutical Companies in the Chinese Hospital Marekt 2005-2007
  • Table 10: Market Concentration Rates of the Chinese Anti-diabetic Drugs Hospital Market 2005 - 2007
  • Table 11: Market Shares and Growth Rates of the Top 10 Anti-diabetic drugs in China (2005-2007)
  • Table 12: Manufacturers, Market Sizes and Shares for Insulin (2006-2007)
  • Table 13: Sales of Insulin from the Top Pharmaceutical Companies in the Chinese Hospital Market 2006-2007
  • Table 14: Manufacturers, Market Sizes and Shares for Acarbose 2006-2007
  • Table 15: Sales of Acarbose from Top Pharmaceutical Companies in the Chinese Hospital Market 2007
  • Table 16: Manufacturers, Market Sizes and Shares for Metformin 2006-2007
  • Table 17: Sales of Metformin from the Top Pharmaceutical Companies in the Chinese Hospital Market 2006-2007
  • Table 18: Manufacturers, Market Sizes and Shares for Repaglinide 2006-2007
  • Table 19: Sales of Repaglinide from the Top Pharmaceutical Companies in the Chinese Hospital Market 2006-2007
  • Table 20: Manufacturers, Market Sizes and Shares for Rosiglitazone 2006-2007
  • Table 21: Sales of Rosiglitazone from the Top Pharmaceutical Companies in the Chinese Hospital Market 2006-2007
  • Table 22: Manufacturers, Market Sizes and Shares for Glipizide 2006-2007
  • Table 23: Sales of Glipizide from the Top Pharmaceutical Companies in the Chinese Hospital Market 2006-2007
  • Table 24: Manufacturers, Market Sizes and Shares for Gliquidone 2006-2007
  • Table 25: Sales of Gliquidone from the Top Pharmaceutical Companies in the Chinese Hospital Market 2007
  • Table 26: Manufacturers, Market Sizes and Shares for Gliclazide 2006-2007
  • Table 27: Sales of Gliclazide from the Top Pharmaceutical Companies in the Chinese Hospital Market 2006-2007
  • Table 28: Manufacturers, Market Sizes and Shares for Nateglinide 2006-2007
  • Table 29: Brand Names, Packages and Retail Prices of Anti-Diabetic Drugs and Their Manufacturers in China 2007
  • Table 30: Anti-diabetics of Western Medicine Covered by the National Basic Healthcare Insurance
  • Table 31: Anti-diabetics of Traditional Chinese Medicine (TCM) Covered by the National Basic Healthcare Insurance
  • Table 32: Anti-diabetic Drugs under Phase II/III Clinical Studies

FIGURES

  • Figure 1: Anti-diabetic Drugs in China
  • Figure 2: Global Market Sizes of Anti-diabetic Drugs (2004-2007)
  • Figure 3: Global Market Size of Oral Anti-diabetic Drugs and Insulin/Insulin Analogs (2003 - 2007)
  • Figure 4: Sizes and Growth Rates of the Chinese Anti-diabetic Drug Market (2002-2007)
  • Figure 5: Market Shares of Different Anti-diabetic Drug Categories in China 2007
  • Figure 6: Market Sizes and Growth Rates of Xiaoke Wan 2005-2007
  • Figure 7: Sales vs. Prescription Volume of None-Insulin Anti-diabetic Drugs in United States (2006)
Show More
Pricing
Not Available
Get Notified
Email me when related reports are published